Abstract: Journal Pre-proof Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a singlecentre randomized, placebo-controlled trial Anant Mohan, Pawan Tiwari, Tejas Menon Suri, Saurabh Mittal, Ankit Patel, Avinash Jain, Velpandian Thirumurthy, Ujjalkumar Subhash Das, Tarun Krishna Boppana, Ravindra Mohan Pandey, Sushil Suresh Shelke, Angel Rajan Singh, Sushma Bhatnagar, Shet Masih, Shelly Mahajan, Tanima Dwivedi, Biswajeet Sahoo, Anuja Pandit, Shweta Bhopale, Saurabh Vig, Ritu Gupta, Karan Madan, Vijay Hadda, Nishkarsh Gupta, Rakesh Garg, Ved Prakash Meena, Randeep Guleria PII: S1341-321X(21)00239-7 DOI: https://doi.org/10.1016/j.jiac.2021.08.021 Reference: JIC 1686 To appear in: Journal of Infection and Chemotherapy Received Date: 26 June 2021 Revised Date: 4 August 2021 Accepted Date: 20 August 2021 Please cite this article as: Mohan A, Tiwari P, Suri TM, Mittal S, Patel A, Jain A, Thirumurthy V, Das US, Boppana TK, Pandey RM, Shelke SS, Singh AR, Bhatnagar S, Masih S, Mahajan S, Dwivedi T, Sahoo B, Pandit A, Bhopale S, Vig S, Gupta R, Madan K, Hadda V, Gupta N, Garg R, Meena VP, Guleria R, Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial, Journal of Infection and Chemotherapy, https://doi.org/10.1016/ j.jiac.2021.08.021. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Title: Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial Authors: Anant Mohana*, Pawan Tiwaria, Tejas Menon Suria, Saurabh Mittala, Ankit Patela, Avinash Jaina, Velpandian Thirumurthyb, Ujjalkumar Subhash Dasb, Tarun Krishna Boppanaa, Ravindra Mohan Pandeyc, Sushil Suresh Shelkea, Angel Rajan Singhd, Sushma Bhatnagare, Shet Masihf, Shelly Mahajanf, Tanima Dwivedig, Biswajeet Sahoog, Anuja Pandite, Shweta Bhopalee, Saurabh Vige, Ritu oo f Guptag, Karan Madana, Vijay Haddaa, Nishkarsh Guptae, Rakesh Garge, Ved Prakash Meenah, re -p r Randeep Guleriaa Author affiliations: a lP Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India Department of Ocular Pharmacology, All India Institute of Medical Sciences, New Delhi, India c Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India d Department of Hospital Administration, All India Institute of Medical Sciences, New Delhi, India e ur na b Jo Department of Onco-Anesthesia, Pain and Palliative Care, All India Institute of Medical Sciences, New Delhi, India f Mahajan Laboratory, New Delhi, India g Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, India h Department of Medicine, All India Institute of Medical Sciences, New Delhi, India * Correspondence..